|
|
Post by mnkdmorelong on Jan 6, 2016 13:00:47 GMT -5
Right now, the SNY reps have been told to not hump Afrezza. I don't think MNKD has another partner lined up quite yet. The SNY contract was dated Aug 2014 and it took six months for the launch to take off. This is normal pacing of business in the pharma business. Can it be expedited? Yes of course. But not that much. I see a lull in marketing activities for the first 6 months of 2016. No forward progress. Keep in mind, MNKD does not have the resources in place to service the market. If they were to start hiring today, It will take 6 months for the troops to start performing. Other than Desisto, who in his right mind would join a company with one foot in the grave?
I know that the Afrezza Luddites will accuse me of bashing. No, its a reality check. There is a lot of heavy lifting that must be done soon.
|
|
|
|
Post by inittowinit on Jan 6, 2016 13:09:05 GMT -5
Your concerns are legit, but is your vision tunneled? IMO, MNKD has many more options at there disposal.
|
|
|
|
Post by mnholdem on Jan 6, 2016 13:14:53 GMT -5
I'd join MannKind in a heartbeat. In fact, I think I may dust off and forward my resume to MannKind's new CEO.
|
|
|
|
Post by tripoley on Jan 6, 2016 13:19:15 GMT -5
I'd join MannKind in a heartbeat. In fact, I think I may dust off and forward my resume to MannKind's new CEO. I'd work for free for stock options. |
|
|
|
Post by avogadro on Jan 6, 2016 13:22:02 GMT -5
...... Other than Desisto, who in his right mind would join a company with one foot in the grave?.......... And what potential patient who is in his right mind would set out on a lifetime commitment to a product sold by a totally dysfunctional company? |
|
|
|
Post by compound26 on Jan 6, 2016 13:25:01 GMT -5
I'd join MannKind in a heartbeat. In fact, I think I may dust off and forward my resume to MannKind's new CEO. mnholdem, I look forward to your joining. Mannkind needs people like you, who have passion in Afrezza and its future. |
|
|
|
Post by mnkdmorelong on Jan 6, 2016 14:09:28 GMT -5
Your concerns are legit, but is your vision tunneled? IMO, MNKD has many more options at there disposal. I want to think you are right. Back in 2014, MNKD's cash dwindled down after AdCom. But Afrezza won the Adcom and was soon granted FDA approval. Affrezza was the fresh face and we all knew money to refill the coffers would come soon. Today, Afrezza is no longer the fresh face and will not fetch a young ingenue's price. Moreover, the cost to support Afrezza will soon be on MNKD. The cash burn that is now $10-15 mln/qtr will soon balloon upwards. |
|
|
|
Post by nylefty on Jan 6, 2016 14:22:10 GMT -5
Right now, the SNY reps have been told to not hump Afrezza. I don't think MNKD has another partner lined up quite yet. The SNY contract was dated Aug 2014 and it took six months for the launch to take off. This is normal pacing of business in the pharma business. Can it be expedited? Yes of course. But not that much. I see a lull in marketing activities for the first 6 months of 2016. No forward progress. Keep in mind, MNKD does not have the resources in place to service the market. If they were to start hiring today, It will take 6 months for the troops to start performing. Other than Desisto, who in his right mind would join a company with one foot in the grave? If MannKind signs an agreement with an established pharma company "today," why would it take 6 months for that pharma's troops to start performing? MannKind doesn't need to hire anybody -- it just needs to make a deal with another company that will put some effort into marketing Afrezza. |
|
|
|
Post by mnkdmorelong on Jan 6, 2016 14:32:07 GMT -5
Right now, the SNY reps have been told to not hump Afrezza. I don't think MNKD has another partner lined up quite yet. The SNY contract was dated Aug 2014 and it took six months for the launch to take off. This is normal pacing of business in the pharma business. Can it be expedited? Yes of course. But not that much. I see a lull in marketing activities for the first 6 months of 2016. No forward progress. Keep in mind, MNKD does not have the resources in place to service the market. If they were to start hiring today, It will take 6 months for the troops to start performing. Other than Desisto, who in his right mind would join a company with one foot in the grave? If MannKind signs an agreement with an established pharma company "today," why would it take 6 months for that pharma's troops to start performing? MannKind doesn't need to hire anybody -- it just needs to make a deal with another company that will put some effort into marketing Afrezza. Like all drugs, Afrezza is a technical sell. SNY started to train their troops 1.5 months before launch. It would take some time for the new marketing department to get all their ducks lined up. New graphics, brochures and such. They have to figure out the compensation plan. Just to write, review and sign the contract will take a month. It's always complicated. |
|
|
|
Post by figglebird on Jan 6, 2016 14:38:58 GMT -5
Here are the facts.
1. The data shows the drug is non inferior when put thru the same fda mandated process and procedure as subq's with respect to administration.
2. When the drug is administered in its designed non fda mandated manner the data reflects an unprecedented capacity to both combat chronic areas of diabetes far more effectively then past and existing medications, while increasing adherence to insulin treatment in what many have reffered to as a needle phobic socioty. Furthermore, it distinguishes itself as a more versatile and corrective treatment that allows some diabetics to enjoy less restrictive diets for the first time and thus lead a more "normal" life.
3. Exhubra, though less effective, showed positive results in its phase 1 pediatric trial, prior to being pulled.
Though analysts schooled in our pharmacutical culture may imply that finding a new partner will be unlikely, I believe what separates winners from losers in any business is the recognition of value in distorted landscapes.
The key is finding ways not to play by their rules. Pfizer failed Sanofi failed.
I would not rule a partner like google out as a source of funding though would probably require a reorginaziton of the company.
Private equity is another place I would look to next along with some foriegn pharma companies both public and private as potential suitors/partners.
Lastly, look for certain established places such as cleaveland clinic to step up.
This is not as binary a situation as it was or as they would have you believe.
|
|
|
|
Post by inittowinit on Jan 6, 2016 14:41:24 GMT -5
So, mnkdmorelong, I've read your comments regarding the future of MNKD. All I read is negative. With all due repect, why not sell and get out "while you can"?
|
|
|
|
Post by savzak on Jan 6, 2016 14:47:42 GMT -5
Momentum? What momentum? You can't lose what you never had. Perhaps we've lost any logical reason for hope to finally achieve momentum. But momentum is something Afrezza has not yet seen.
|
|
|
|
Post by blindhog1 on Jan 6, 2016 15:02:16 GMT -5
...... Other than Desisto, who in his right mind would join a company with one foot in the grave?.......... And what potential patient who is in his right mind would set out on a lifetime commitment to a product sold by a totally dysfunctional company? Patients that have fantastic results are excellent reps. Even I have an old dusty resume. I like the prospects MNKD has now that SNY isn't trying to bleed us to death. Stock Options, mileage and a protected territory.
|
|
|
|
Post by nylefty on Jan 6, 2016 15:10:00 GMT -5
If MannKind signs an agreement with an established pharma company "today," why would it take 6 months for that pharma's troops to start performing? MannKind doesn't need to hire anybody -- it just needs to make a deal with another company that will put some effort into marketing Afrezza. Like all drugs, Afrezza is a technical sell. SNY started to train their troops 1.5 months before launch. It would take some time for the new marketing department to get all their ducks lined up. New graphics, brochures and such. They have to figure out the compensation plan. Just to write, review and sign the contract will take a month. It's always complicated. So it might take two or three months for the new company to get up to speed. Meanwhile, docs would continue to prescribe Afrezza and pharmacies would continue to sell it, as they do now. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 6, 2016 15:13:56 GMT -5
So, mnkdmorelong, I've read your comments regarding the future of MNKD. All I read is negative. With all due repect, why not sell and get out "while you can"? What is currently positive? Let the guy vent a bit if he needs too |
|
